You are here

Article Text

Article menu
Download PDFPDF
Letter
Recurrent uveitis in a patient with juvenile spondyloarthropathy associated with tumour necrosis factor α inhibitors
  1. O Kaipiainen-Seppänen1,
  2. M Leino2
  1. 1Department of Medicine, Kuopio University Hospital, Kuopio, Finland
  2. 2Department of Ophthalmology, Kuopio University Hospital, Kuopio, Finland
  1. Correspondence to:
    Dr O Kaipiainen-Seppänen, Department of Medicine, Kuopio University Hospital, PO Box 1777, 70211 Kuopio, Finland;
    Oili.Kaipiainen-Seppanen{at}kuh.fi

https://doi.org/10.1136/ard.62.1.88

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Tumour necrosis factor α (TNFα) antagonists have been shown to be effective in controlling symptoms in patients with rheumatoid arthritis (RA)1,2 and juvenile RA (JRA).1 The most common adverse events associated with etanercept are injection site reactions and infections, and with infliximab, headache, infections and, occasionally, infusion related reactions.2 Cutaneous vasculitis associated with etanercept has been described in three patients, and one of them also had a similar skin manifestation secondary to the treatment with infliximab.3 The possible association of a demyelinating syndrome with the use of anti-TNF agents in inflammatory arthritides needs further surveillance.4

    CASE REPORT

    A 31 year old female patient has had juvenile rheumatic disease since the age of 10. She has had a polyarticular disease in her peripheral joints with inflammatory manifestations both in the cervical spine and sacroiliac joints. She is HLA-B27 positive. At the time of diagnosis she was treated with aurothiomalate and hydroxychloroquine, but they were withdrawn because …

    View Full Text